ADC-051

ADC-051 is a preclinical-stage antibody-drug conjugate (ADC) being developed by iProgen Biotech for the treatment of neurodegenerative diseases. The asset utilizes a monoclonal antibody to deliver a small molecule payload to specific targets within the central nervous system, leveraging iProgen's proprietary ADC platform technology. The program is being developed through an academic partnership. While the specific molecular target and the nature of the small molecule payload have not been publicly disclosed, the drug is designed to apply the targeted delivery advantages of the ADC modality to address unmet needs in neurodegeneration.